Home › Free Stock Grades › KPTI
Karyopharm Therapeutics Inc. (KPTI) Stock Grade
KPTI · Healthcare
B+
Market Cap
$80.5M
P/E Ratio
—
Revenue Growth (YoY)
+0.6%
Net Margin
-134.2%
Return on Equity
66.9%
Dividend Yield
None
About Karyopharm Therapeutics Inc.'s fundamentals
Karyopharm Therapeutics is a small-cap biotechnology company with a market capitalization of $80.5 million that reported minimal revenue growth of 0.6% year-over-year. The company is unprofitable, with a net margin of -134.2% and a reported net loss in its latest annual statement, which is common for early-stage biotech firms investing heavily in research and development. The company does not pay a dividend. The reported return on equity of 66.9% reflects the company's negative earnings relative to its equity base rather than operational profitability.